The University of Chicago Header Logo

Connection

Thomas F. Gajewski to Quinazolines

Back to Details
This is a "connection" page, showing publications Thomas F. Gajewski has written about Quinazolines.
Thomas F. Gajewski
Connection Strength
0.502
Quinazolines
  1. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
    View in: PubMed
    Score: 0.382
  2. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs. 2016 Apr; 34(2):231-5.
    View in: PubMed
    Score: 0.119
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.